Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06079398




Registration number
NCT06079398
Ethics application status
Date submitted
6/10/2023
Date registered
12/10/2023
Date last updated
23/04/2024

Titles & IDs
Public title
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
Scientific title
A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Trial, Evaluating Safety, Tolerability, and Efficacy of Subcutaneous Doses of TransCon CNP Administered Once Weekly for 52 Weeks in Infants (0 to <2 Years of Age) With Achondroplasia Followed by an Open Label Extension (OLE) Period
Secondary ID [1] 0 0
ASND0030
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Achondroplasia 0 0
Condition category
Condition code
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders
Musculoskeletal 0 0 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Navepegritide
Treatment: Drugs - Placebo for Navepegritide

Experimental: Navepegritide - Once weekly double-blinded treatment with SC injection of 100 µg/kg of Navepegritide for 52 weeks

Placebo Comparator: Placebo for Navepegritide - Once weekly double-blinded treatment with SC injection of 100 µg/kg of Placebo for Navepegritide for 52 weeks


Treatment: Drugs: Navepegritide
Once-weekly subcutaneous injection of 100 µg/kg Navepegritide

Treatment: Drugs: Placebo for Navepegritide
Once-weekly subcutaneous injection of 100 µg/kg placebo for Navepegritide
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
To evaluate the safety and tolerability of Navepegritide
Timepoint [1] 0 0
52 weeks
Primary outcome [2] 0 0
To evaluate the effect of Navepegritide on growth
Timepoint [2] 0 0
52 weeks

Eligibility
Key inclusion criteria
- Written, signed informed consent by the parent(s)/caregiver(s) of the participant, and
as required by the institutional review board/human research ethics
committee/independent ethics committee (IRB/HREC/IEC).

- Male or female younger than 2 years of age at the time of randomization; or for open
label sentinel participants, at the time of first administration of IMP.

- Clinical diagnosis of achondroplasia (ACH) with genetic confirmation of heterozygous
genotype present during screening.

- Parent(s)/caregiver(s) willing to follow the protocol and instructions provided,
including being able to administer weekly subcutaneous injections of trial treatment.

- Compliance to daily Vitamin D supplementation for infants aged 14 days to 1 year. All
participants older than 1 year of age with serum 25-hydroxyvitamin D (25OHD) measured
below lower limit of reference range at screening should start daily Vitamin D
supplementation prior to randomization.

- Considered eligible based on the medical history, physical examination, and the
results of vital signs, ECG, imaging, and clinical laboratory tests performed during
the screening period.
Minimum age
0 Years
Maximum age
2 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Known or suspected hypersensitivity to the investigational product or related products
(trehalose, tris[hydroxymethyl]aminomethane, succinate, and polyethylene glycol
[PEG]).

- Genetic confirmation of ACH homozygous genotype.

- Premature birth with gestational age < 32 weeks.

- Premature birth with gestational age 32 to 37 weeks, unless time from birth is > 6
months at the time of screening and the child is in good nutritional status, defined
as gain in body weight expected for age and diagnosis of ACH, as determined by the
Investigator and confirmed with the Medical Monitor.

- Anticipated, as assessed by Investigator and confirmed with Medical Monitor, to
undergo surgical intervention during trial participation, including cervicomedullary
decompression. Evaluation of immediate risk of requiring cervicomedullary
decompression surgery will rely on the following assessments:

- Physical examination (e.g., neurologic findings of clonus, opisthotonus,
exaggerated reflexes, dilated facial veins)

- Evidence of uncontrolled sleep apnea as confirmed by local standard of care
assessment (e.g. polysomnography or simple sleep test) performed within 6 months
prior to screening.

- MRI performed at screening indicating presence of severe cervicomedullary
compression (CMC) or spinal cord damage. Presence of abnormal MRI T2 signal
intensity at and immediately above and below the cervicomedullary junction should
be considered high risk for requiring surgery and the participant is not eligible
for trial participation.

Common surgeries, such as insertion of grommets, adenoidectomy, tonsillectomy, or
myringotomy tube placement are permitted during trial participation.

- Have a growth disorder or medical condition, other than ACH, resulting in short
stature or abnormal growth as determined by the Investigator and confirmed with the
Medical Monitor.

- Have received any dose of prescription medications and/or investigational medicinal
product or device intended to affect stature, growth, or body proportionality
(including human growth hormone or vosoritide) at any time.

- Requires or anticipated to require chronic (> 4 weeks) or repeated treatment (more
than twice/year) with oral corticosteroids, or high-dose inhaled corticosteroids
during trial participation.

- History or presence of injury or disease of the growth plate(s), other than ACH,
affecting growth potential of long bones, including Salter-Harris fracture and recent
bone-related surgery, as determined by Investigator and confirmed with the Medical
Monitor.

- Have a clinically significant finding indicating abnormal cardiac function, including
but not limited to:

- Repaired or unrepaired coarctation.

- Moderate or greater complexity congenital heart disease including tetralogy of
Fallot, atrioventricular septal defects, truncus arteriosus, total anomalous
pulmonary venous return, double outlet right ventricle, or single ventricle heart
disease.

- QTcF = 450 msec on screening 12-lead ECG.

- History or presence of a condition impacting hemodynamic stability (such as autonomic
dysfunction and orthostatic intolerance).

- History or presence of the following:

- Chronic anemia.

- Chronic renal insufficiency.

- Chronic or recurrent illness that can affect hydration or volume status,
including conditions associated with decreased nutritional intake or increased
volume loss.

- History or presence of malignant disease.

- Any disease or condition that, in the opinion of the Investigator, may make the
participant unlikely to fully complete the trial, not adhering to trial procedures,
may confound interpretation of trial results, or may present undue risk from receiving
trial treatment. This could include family situations, comorbid conditions, or
medications that might impact safety or be considered confounding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
23/01/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/03/2027
Actual
Sample size
Target
72
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Ascendis Investigational Site - Parkville
Recruitment postcode(s) [1] 0 0
3052 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Minnesota
Country [2] 0 0
United States of America
State/province [2] 0 0
Texas
Country [3] 0 0
United States of America
State/province [3] 0 0
Wisconsin

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Ascendis Pharma Growth Disorders A/S
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This trial is a Phase 2, multicenter, double-blind, randomized (ratio 2:1 TransCon CNP vs.
placebo), placebo-controlled trial, designed to evaluate the safety, tolerability, and
efficacy of 100 µg CNP/kg of Navepegritide (TransCon CNP) administered SC once-weekly for 52
weeks in infants with genetically verified heterozygous ACH, aged 0 to < 2 years at the time
of randomization.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06079398
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Vibeke Breinholt
Address 0 0
Country 0 0
Phone 0 0
+4561242484
Fax 0 0
Email 0 0
vib@ascendispharma.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06079398